{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:58Z","timestamp":1792194958716,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00358981"],"award-info":[{"award-number":["RS-2024-00358981"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00227084"],"award-info":[{"award-number":["RS-2023-00227084"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1F1A1073962"],"award-info":[{"award-number":["NRF-2020R1F1A1073962"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2024IP0086"],"award-info":[{"award-number":["2024IP0086"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,9,5]]},"DOI":"10.1038\/s41416-026-03475-1","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:23:15Z","timestamp":1779762195000},"page":"830-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6065-4845","authenticated-orcid":false,"given":"Seok Soon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ri","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seol Hwa","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga Won","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong Joon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Jung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyung","family":"Rho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-1997","authenticated-orcid":false,"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-8345","authenticated-orcid":false,"given":"Si Yeol","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-5488","authenticated-orcid":false,"given":"Seong-Yun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"3475_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3475_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2019.09.017","volume":"137","author":"ACZ Gelatti","year":"2019","unstructured":"Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113\u201322.","journal-title":"Lung Cancer"},{"key":"3475_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367\u201380.","journal-title":"N Engl J Med"},{"key":"3475_CR4","doi-asserted-by":"crossref","unstructured":"Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers. 2021;13:2748.","DOI":"10.3390\/cancers13112748"},{"key":"3475_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103454","volume":"166","author":"F Papini","year":"2021","unstructured":"Papini F, Sundaresan J, Leonetti A, Tiseo M, Rolfo C, Peters GJ, et al. Hype or hope\u2014can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced\/metastatic NSCLC? Crit Rev Oncol Hematol. 2021;166:103454.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3475_CR6","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.21037\/tcr.2018.10.06","volume":"8","author":"N Karachaliou","year":"2019","unstructured":"Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Transl Cancer Res. 2019;8:S23\u2013s47.","journal-title":"Transl Cancer Res"},{"key":"3475_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38.","journal-title":"Mol Cancer"},{"key":"3475_CR8","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240\u20137.","journal-title":"Clin Cancer Res"},{"key":"3475_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nm.2713","volume":"18","author":"KP Ng","year":"2012","unstructured":"Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:521\u20138.","journal-title":"Nat Med"},{"key":"3475_CR10","doi-asserted-by":"publisher","first-page":"7854","DOI":"10.1158\/0008-5472.CAN-06-1951","volume":"66","author":"M Inukai","year":"2006","unstructured":"Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66:7854\u20138.","journal-title":"Cancer Res"},{"key":"3475_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10020-020-00193-z","volume":"26","author":"D Sun","year":"2020","unstructured":"Sun D, Zhu Y, Zhu J, Tao J, Wei X, Wo Y, et al. Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC. Mol Med. 2020;26:66.","journal-title":"Mol Med"},{"key":"3475_CR12","doi-asserted-by":"publisher","first-page":"71358","DOI":"10.18632\/oncotarget.20311","volume":"8","author":"WZ Zhong","year":"2017","unstructured":"Zhong WZ, Zhou Q, Wu YL. The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer. Oncotarget. 2017;8:71358\u201370.","journal-title":"Oncotarget"},{"key":"3475_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1541-7786.MCR-16-0482","volume":"15","author":"T Yamaoka","year":"2017","unstructured":"Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, et al. Distinct afatinib resistance mechanisms identified in lung adenocarcinoma harboring an EGFR mutation. Mol Cancer Res. 2017;15:915\u201328.","journal-title":"Mol Cancer Res"},{"key":"3475_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","volume":"28","author":"D Jackman","year":"2010","unstructured":"Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, J\u00e4nne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357\u201360.","journal-title":"J Clin Oncol"},{"key":"3475_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390\u2013401.","journal-title":"Acta Pharm Sin B"},{"key":"3475_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA J\u00e4nne","year":"2015","unstructured":"J\u00e4nne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689\u201399.","journal-title":"N Engl J Med"},{"key":"3475_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jjco\/hyad052","volume":"53","author":"T Araki","year":"2023","unstructured":"Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Jpn J Clin Oncol. 2023;53:547\u201361.","journal-title":"Jpn J Clin Oncol"},{"key":"3475_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/atm.2018.12.68","volume":"7","author":"CK Liam","year":"2019","unstructured":"Liam CK. Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer. Ann Transl Med. 2019;7:61.","journal-title":"Ann Transl Med"},{"key":"3475_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","volume":"14","author":"BC Cho","year":"2019","unstructured":"Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, et al. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. J Thorac Oncol. 2019;14:99\u2013106.","journal-title":"J Thorac Oncol"},{"key":"3475_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107895","volume":"194","author":"M Wespiser","year":"2024","unstructured":"Wespiser M, Swalduz A, P\u00e9rol M. Treatment sequences in EGFR mutant advanced NSCLC. Lung Cancer. 2024;194:107895.","journal-title":"Lung Cancer"},{"key":"3475_CR21","doi-asserted-by":"publisher","unstructured":"Herbst RS, John T, Groh\u00e9 C, Goldman JW, Kato T, Laktionov K, et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03577-y.","DOI":"10.1038\/s41591-025-03577-y"},{"key":"3475_CR22","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/ejhg.2016.25","volume":"24","author":"V Nofrini","year":"2016","unstructured":"Nofrini V, Di Giacomo D, Mecucci C. Nucleoporin genes in human diseases. Eur J Hum Genet. 2016;24:1388\u201395.","journal-title":"Eur J Hum Genet"},{"key":"3475_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.cell.2010.01.011","volume":"140","author":"B Kalverda","year":"2010","unstructured":"Kalverda B, Pickersgill H, Shloma VV, Fornerod M. Nucleoporins directly stimulate expression of developmental and cell-cycle genes inside the nucleoplasm. Cell. 2010;140:360\u201371.","journal-title":"Cell"},{"key":"3475_CR24","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1128\/MCB.00649-09","volume":"29","author":"PC Echeverr\u00eda","year":"2009","unstructured":"Echeverr\u00eda PC, Mazaira G, Erlejman A, Gomez-Sanchez C, Piwien Pilipuk G, Galigniana MD. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin b. eta. Mol Cell Biol. 2009;29:4788\u201397.","journal-title":"eta. Mol Cell Biol"},{"key":"3475_CR25","doi-asserted-by":"publisher","first-page":"e21078","DOI":"10.1371\/journal.pone.0021078","volume":"6","author":"T Zhou","year":"2011","unstructured":"Zhou T, Li S, Zhong W, Vihervaara T, B\u00e9aslas O, Perttil\u00e4 J, et al. OSBP-related protein 8 (ORP8) regulates plasma and liver tissue lipid levels and interacts with the nucleoporin Nup62. PLoS One. 2011;6:e21078.","journal-title":"PLoS One"},{"key":"3475_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1095046","volume":"13","author":"U Singh","year":"2023","unstructured":"Singh U, Bindra D, Samaiya A, Mishra RK. Overexpressed Nup88 stabilized through interaction with Nup62 promotes NF-\u03baB dependent pathways in cancer. Front Oncol. 2023;13:1095046.","journal-title":"Front Oncol"},{"key":"3475_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1559396","volume":"16","author":"L Chen","year":"2025","unstructured":"Chen L, He Y, Duan M, Yang T, Chen Y, Wang B, et al. Exploring NUP62\u2019s role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis. Front Immunol. 2025;16:1559396.","journal-title":"Front Immunol"},{"key":"3475_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15252\/embr.201745497","volume":"19","author":"J Borlido","year":"2018","unstructured":"Borlido J, D\u2019Angelo MA. Nup62-mediated nuclear import of p63 in squamous cell carcinoma. EMBO Rep. 2018;19:3\u20134.","journal-title":"EMBO Rep"},{"key":"3475_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.15252\/embr.201744523","volume":"19","author":"M Hazawa","year":"2018","unstructured":"Hazawa M, Lin DC, Kobayashi A, Jiang YY, Xu L, Dewi FRP, et al. ROCK-dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation. EMBO Rep. 2018;19:73\u201388.","journal-title":"EMBO Rep"},{"key":"3475_CR30","doi-asserted-by":"crossref","unstructured":"Ji W, Choi YJ, Kang MH, Sung KJ, Kim DH, Jung S, et al. Efficacy of the CDK7 inhibitor on EMT-associated resistance to 3rd generation EGFR-TKIs in non-small cell lung cancer cell lines. Cells. 2020;9:2596.","DOI":"10.3390\/cells9122596"},{"key":"3475_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99267-z","volume":"11","author":"S Jung","year":"2021","unstructured":"Jung S, Kim DH, Choi YJ, Kim SY, Park H, Lee H, et al. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Sci Rep. 2021;11:19667.","journal-title":"Sci Rep"},{"key":"3475_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ajpath.2011.09.024","volume":"180","author":"Y Kinoshita","year":"2012","unstructured":"Kinoshita Y, Kalir T, Rahaman J, Dottino P, Kohtz DS. Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. Am J Pathol. 2012;180:375\u201389.","journal-title":"Am J Pathol"},{"key":"3475_CR33","doi-asserted-by":"crossref","unstructured":"Lu Y, Bian D, Zhang X, Zhang H, Zhu Z. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer. Mol Med Rep. 2021;23:48.","DOI":"10.3892\/mmr.2020.11686"},{"key":"3475_CR34","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.21873\/anticanres.15237","volume":"41","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Seino S, Sugai A, et al. Lurasidone sensitizes cancer cells to osimertinib by inducing autophagy and reduction of survivin. Anticancer Res. 2021;41:4321\u201331.","journal-title":"Anticancer Res"},{"key":"3475_CR35","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/2767-9764.CRC-22-0066","volume":"2","author":"MJ Martin","year":"2022","unstructured":"Martin MJ, Floc\u2019h N, Pfeifer M, Criscione S, Delpuech O, Gagrica S, et al. Pharmaceutical reactivation of attenuated apoptotic pathways leads to elimination of osimertinib drug-tolerant cells. Cancer Res Commun. 2022;2:1312\u201325.","journal-title":"Cancer Res Commun"},{"key":"3475_CR36","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00204-020-02816-0","volume":"94","author":"Z Liu","year":"2020","unstructured":"Liu Z, Gao W. Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells. Arch Toxicol. 2020;94:3125\u201336.","journal-title":"Arch Toxicol"},{"key":"3475_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13046-020-01593-z","volume":"39","author":"M Li","year":"2020","unstructured":"Li M, Gao F, Yu X, Zhao Q, Zhou L, Liu W, et al. Promotion of ubiquitination-dependent survivin destruction contributes to xanthohumol-mediated tumor suppression and overcomes radioresistance in human oral squamous cell carcinoma. J Exp Clin Cancer Res. 2020;39:88.","journal-title":"J Exp Clin Cancer Res"},{"key":"3475_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7150\/ijbs.87180","volume":"20","author":"J Liao","year":"2024","unstructured":"Liao J, Qing X, Li X, Gan Y, Wang R, Han S, et al. TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance. Int J Biol Sci. 2024;20:182\u201399.","journal-title":"Int J Biol Sci"},{"key":"3475_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u201361.","journal-title":"Cancer Discov"},{"key":"3475_CR40","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.2217\/fon.15.250","volume":"11","author":"J Remon","year":"2015","unstructured":"Remon J, Planchard D. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol. 2015;11:3069\u201381.","journal-title":"Future Oncol"},{"key":"3475_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173.","journal-title":"J Hematol Oncol"},{"key":"3475_CR42","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.21037\/jtd.2019.08.31","volume":"12","author":"AI Velazquez","year":"2020","unstructured":"Velazquez AI, McCoach CE. Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. J Thorac Dis. 2020;12:2896\u2013909.","journal-title":"J Thorac Dis"},{"key":"3475_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, Strittmatter N, Yan Y, Wrigley GL, et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27:189\u2013201.","journal-title":"Clin Cancer Res"},{"key":"3475_CR44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.canlet.2018.02.004","volume":"420","author":"ZH Tang","year":"2018","unstructured":"Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018;420:242\u20136.","journal-title":"Cancer Lett"},{"key":"3475_CR45","doi-asserted-by":"publisher","first-page":"19321","DOI":"10.1074\/jbc.M703222200","volume":"282","author":"Y Leng","year":"2007","unstructured":"Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007;282:19321\u201330.","journal-title":"J Biol Chem"},{"key":"3475_CR46","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.1093\/nar\/gky569","volume":"46","author":"G Rodriguez-Berriguete","year":"2018","unstructured":"Rodriguez-Berriguete G, Granata G, Puliyadi R, Tiwana G, Prevo R, Wilson RS, et al. Nucleoporin 54 contributes to homologous recombination repair and post-replicative DNA integrity. Nucleic Acids Res. 2018;46:7731\u201346.","journal-title":"Nucleic Acids Res"},{"key":"3475_CR47","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.3390\/ijms15022494","volume":"15","author":"M Mobahat","year":"2014","unstructured":"Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014;15:2494\u2013516.","journal-title":"Int J Mol Sci"},{"key":"3475_CR48","first-page":"399","volume":"8","author":"D Li","year":"2018","unstructured":"Li D, Hu C, Li H. Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed Rep. 2018;8:399\u2013406.","journal-title":"Biomed Rep"},{"key":"3475_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122788","volume":"350","author":"G Siragusa","year":"2024","unstructured":"Siragusa G, Tomasello L, Giordano C, Pizzolanti G. Survivin (BIRC5): implications in cancer therapy. Life Sci. 2024;350:122788.","journal-title":"Life Sci"},{"key":"3475_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","volume":"70","author":"CM Pickart","year":"2001","unstructured":"Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503\u201333.","journal-title":"Annu Rev Biochem"},{"key":"3475_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/07853890310016324","volume":"36","author":"P Roos-Mattjus","year":"2004","unstructured":"Roos-Mattjus P, Sistonen L. The ubiquitin-proteasome pathway. Ann Med. 2004;36:285\u201395.","journal-title":"Ann Med"},{"key":"3475_CR52","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.15896","volume":"114","author":"SS Park","year":"2023","unstructured":"Park SS, Kwon MR, Ju EJ, Shin SH, Park J, Ko EJ, et al. Targeting phosphomevalonate kinase enhances radiosensitivity via ubiquitination of the replication protein A1 in lung cancer cells. Cancer Sci. 2023;114:3583\u201394.","journal-title":"Cancer Sci"},{"key":"3475_CR53","doi-asserted-by":"publisher","first-page":"11843","DOI":"10.1074\/jbc.M114.629931","volume":"290","author":"Y Liu","year":"2015","unstructured":"Liu Y, Lear T, Iannone O, Shiva S, Corey C, Rajbhandari S, et al. The proapoptotic F-box protein Fbxl7 regulates mitochondrial function by mediating the ubiquitylation and proteasomal degradation of survivin. J Biol Chem. 2015;290:11843\u201352.","journal-title":"J Biol Chem"},{"key":"3475_CR54","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.molcel.2014.03.046","volume":"54","author":"Z Li","year":"2014","unstructured":"Li Z, Pei XH, Yan J, Yan F, Cappell KM, Whitehurst AW, et al. CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol Cell. 2014;54:805\u201319.","journal-title":"Mol Cell"},{"key":"3475_CR55","doi-asserted-by":"publisher","first-page":"26202","DOI":"10.1074\/jbc.M700776200","volume":"282","author":"V Arora","year":"2007","unstructured":"Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem. 2007;282:26202\u20139.","journal-title":"J Biol Chem"},{"key":"3475_CR56","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1600-0854.2006.00486.x","volume":"7","author":"RH Stauber","year":"2006","unstructured":"Stauber RH, Rabenhorst U, Rekik A, Engels K, Bier C, Knauer SK. Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic. 2006;7:1461\u201372.","journal-title":"Traffic"},{"key":"3475_CR57","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1158\/1078-0432.CCR-15-0408","volume":"21","author":"F Conforti","year":"2015","unstructured":"Conforti F, Wang Y, Rodriguez JA, Alberobello AT, Zhang YW, Giaccone G. Molecular Pathways: anticancer activity by inhibition of nucleocytoplasmic shuttling. Clin Cancer Res. 2015;21:4508\u201313.","journal-title":"Clin Cancer Res"},{"key":"3475_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.34","volume":"1","author":"KS Chan","year":"2010","unstructured":"Chan KS, Wong CH, Huang YF, Li HY. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis. 2010;1:e57.","journal-title":"Cell Death Dis"},{"key":"3475_CR59","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1242\/jcs.113.23.4363","volume":"113","author":"J Zhao","year":"2000","unstructured":"Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113:4363\u201371.","journal-title":"J Cell Sci"},{"key":"3475_CR60","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1074\/jbc.M704461200","volume":"283","author":"CM Connell","year":"2008","unstructured":"Connell CM, Colnaghi R, Wheatley SP. Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem. 2008;283:3289\u201396.","journal-title":"J Biol Chem"},{"key":"3475_CR61","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11912-012-0215-2","volume":"14","author":"DN Church","year":"2012","unstructured":"Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14:120\u20138.","journal-title":"Curr Oncol Rep"},{"key":"3475_CR62","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117\u201334.","journal-title":"Cell"},{"key":"3475_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0793-1","volume":"17","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53.","journal-title":"Mol Cancer"},{"key":"3475_CR64","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","volume":"5","author":"KR Jakobsen","year":"2016","unstructured":"Jakobsen KR, Demuth C, Sorensen BS, Nielsen AL. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2016;5:172\u201382.","journal-title":"Transl Lung Cancer Res"},{"key":"3475_CR65","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bbrc.2023.09.047","volume":"681","author":"M Jing","year":"2023","unstructured":"Jing M, He X, Cai CZ, Ma QZ, Li K, Zhang BX, et al. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer. Biochem Biophys Res Commun. 2023;681:218\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"3475_CR66","doi-asserted-by":"crossref","unstructured":"Nishihara S, Yamaoka T, Ishikawa F, Higuchi K, Hasebe Y, Manabe R, et al. Mechanisms of EGFR-TKI-induced apoptosis and strategies targeting apoptosis in EGFR-mutated non-small cell lung cancer. Genes. 2022;13:2183.","DOI":"10.3390\/genes13122183"},{"key":"3475_CR67","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/med.21547","volume":"39","author":"D Mart\u00ednez-Garc\u00eda","year":"2019","unstructured":"Mart\u00ednez-Garc\u00eda D, Manero-Rup\u00e9rez N, Quesada R, Korrodi-Greg\u00f3rio L, Soto-Cerrato V. Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev. 2019;39:887\u2013909.","journal-title":"Med Res Rev"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03475-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:02:14Z","timestamp":1786939334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03475-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,5]]}},"alternative-id":["3475"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03475-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were performed following a protocol approved by the Institutional Animal Care and Use Committee of the Asan Institute for Life Science (2024-40-038). Sample sizes of animal experiments were calculated using the \u2018resource equation\u2019: E\u2009=\u2009total number of animals\u2009\u2212\u2009total number of groups, in which E should lie between 10 and 20. All patients provided signed informed consent. This study was approved by the Institutional Review Board (IRB) of Asan Medical Center (2014-0214).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors agree to submit this article for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}